TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Prescient Therapeutics Limited ( (AU:PTX) ) has provided an announcement.
Prescient Therapeutics Limited has secured Orphan Drug Designation from the European Medicines Agency for PTX-100, a therapy for cutaneous T-cell lymphoma (CTCL), which provides significant benefits such as 10 years of market exclusivity in the EU upon approval. This designation underscores the urgent need for new CTCL treatments and validates PTX-100’s potential to benefit patients across Europe, enhancing Prescient’s commercial pathway in key markets.
More about Prescient Therapeutics Limited
Prescient Therapeutics Limited is a clinical-stage oncology company specializing in personalized cancer treatments through advanced targeted and cellular therapies. Their key product, PTX-100, is a first-in-class compound that targets cancer growth pathways by inhibiting the enzyme geranylgeranyl transferase-1 (GGT-1), which disrupts oncogenic Ras pathways and induces cancer cell apoptosis. The company is also developing innovative cell therapy platforms, including CellPryme-M and CellPryme-A, to enhance the efficacy of adoptive cell therapies, and OmniCAR, a universal immune receptor platform for controllable T-cell activity.
Average Trading Volume: 823,243
Technical Sentiment Signal: Buy
Current Market Cap: A$49.42M
Learn more about PTX stock on TipRanks’ Stock Analysis page.